Sign in Subscribe

immunotherapy

A collection of 61 issues

Dual immunotherapy may outperform single-agent pembrolizumab in MSI-H metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Dual immunotherapy may outperform single-agent pembrolizumab in MSI-H metastatic colorectal cancer An indirect comparison using reconstructed patient data from KEYNOTE-177 and CheckMate 8HW suggests nivolumab-ipilimumab may offer progression-free survival benefits over pembrolizumab in first-line MSI-H/dMMR metastatic disease, though grade 3/4

TAP1 deficiency creates new immunotherapy targets in colorectal cancer

Skip to content The CRC Digest ◇ RESEARCH TAP1 deficiency creates new immunotherapy targets in colorectal cancer Loss of TAP1, an immune escape mechanism found in 26% of colorectal cancers, generates alternative T cell epitopes that may be exploitable for immunotherapy; researchers identified CD8 T cells from patient tumors that can

Targeting peripheral serotonin receptor enhances antitumor immunity in colorectal cancer

Skip to content The CRC Digest ◇ RESEARCH Targeting peripheral serotonin receptor enhances antitumor immunity in colorectal cancer Researchers developed IHCH-8110, a non-brain-penetrant 5-HT2AR agonist that activates serotonin receptors on enteric glial cells to promote CD8+ T cell recruitment and suppress colorectal cancer growth without psychedelic effects. (Cell) This content is

Economic evaluation compares nivolumab plus ipilimumab versus nivolumab alone in dMMR/MSI-H metastatic CRC

Skip to content The CRC Digest Economic evaluation compares nivolumab plus ipilimumab versus nivolumab alone in dMMR/MSI-H metastatic CRC A Chinese study used a three-state partitioned survival model to evaluate nivolumab plus ipilimumab versus nivolumab monotherapy in previously treated metastatic colorectal cancer patients with dMMR/MSI-H, using Kaplan-Meier curves

Case report shows successful re-challenge with encorafenib, cetuximab, and nivolumab in BRAF V600E cancer

Skip to content The CRC Digest ▸ TREATMENT Case report shows successful re-challenge with encorafenib, cetuximab, and nivolumab in BRAF V600E cancer A patient with BRAF V600E mutated, mismatch-repair-proficient metastatic colorectal cancer responded to re-challenge with encorafenib and cetuximab combined with nivolumab after prior progression, suggesting this combination may offer renewed

Phase 2 study evaluates pembrolizumab combination for MSS/pMMR metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Phase 2 study evaluates pembrolizumab combination for MSS/pMMR metastatic colorectal cancer A Phase II study tested pembrolizumab plus capecitabine and bevacizumab in microsatellite stable/mismatch repair-proficient metastatic colorectal cancer, a population that typically does not respond well to immunotherapy alone. (Clinical

Phase 2 trial tests dostarlimab plus chemotherapy before surgery in stage III colon cancer

Skip to content The CRC Digest ◆ TRIAL DATA Phase 2 trial tests dostarlimab plus chemotherapy before surgery in stage III colon cancer The AZUR-4 trial is comparing neoadjuvant dostarlimab plus CAPEOX versus CAPEOX alone in previously untreated T4N0 or stage III mismatch repair proficient/microsatellite stable resectable colon cancer. (Clinical

GPR39 Protein Linked to Immunotherapy Resistance in Microsatellite-Stable CRC

Skip to content The CRC Digest ◇ RESEARCH GPR39 Protein Linked to Immunotherapy Resistance in Microsatellite-Stable CRC Research using GPR39 knockdown in human and mouse CRC cell lines found that GPR39, a protein overexpressed in colorectal cancer, suppresses ferroptosis (a form of cell death) and reduces the sensitivity of microsatellite-stable tumors

Review examines circulating tumor DNA and immune biomarkers for detecting molecular residual disease

Skip to content The CRC Digest Review examines circulating tumor DNA and immune biomarkers for detecting molecular residual disease A comprehensive review discusses how ctDNA and immune biomarkers such as mismatch repair deficiency, microsatellite instability, and tumor mutational burden can identify patients at high risk of recurrence and guide adjuvant

Gut microbiome and metabolite profiles differ between immunotherapy responders and non-responders

Skip to content The CRC Digest ◇ RESEARCH Gut microbiome and metabolite profiles differ between immunotherapy responders and non-responders In 20 patients with MSI-H advanced colorectal cancer receiving immunotherapy, metagenomic sequencing and metabolomics revealed distinct gut microbiota and metabolite patterns associated with clinical benefit versus non-benefit, suggesting the microbiome may influence